The regulation of plasminogen activator inhibitor-1 (PAI-1) production with dexamethasone by human lung fibroblasts

K. Takahashi, K. Kobayashi, M. Mitsui, T. Odaka, H. Nakamura, T. Matsuoka (Ami, Japan)

Source: Annual Congress 2005 - Cellular and molecular aspects of lung injury
Session: Cellular and molecular aspects of lung injury
Session type: Thematic Poster Session
Number: 2241
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Takahashi, K. Kobayashi, M. Mitsui, T. Odaka, H. Nakamura, T. Matsuoka (Ami, Japan). The regulation of plasminogen activator inhibitor-1 (PAI-1) production with dexamethasone by human lung fibroblasts. Eur Respir J 2005; 26: Suppl. 49, 2241

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Human lung microvascular endothelial cells (HMVEC-L) angiogenic activity is inhibited by stable plasminogen activator inhibitor-1 (PAI-1) mutants via urokinase-dependent pathway
Source: Annual Congress 2004 - Lung development and cancer
Year: 2004


Pro-urokinase up-regulates the expression of urokinase type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells
Source: Eur Respir J 2007; 30: Suppl. 51, 143s
Year: 2007

The effect of prostaglandin (PG) E2 and its receptor antagonists on urokinase-type plasminogen activator (uPA) production by human lung fibroblasts
Source: Eur Respir J 2006; 28: Suppl. 50, 811s
Year: 2006

Upregulation of the gene encoding the urokinase-type plasminogen activator (uPA) in respiratory muscles of COPD patients
Source: Annual Congress 2004 - Skeletal muscle in respiratory disease
Year: 2004


Plasminogen activator inhibitor-1 (PAI-1) mutations of extended half-life time inhibit angiogenic properties of human lung microvascular endothelial cells (HMVEC-L)
Source: Eur Respir J 2003; 22: Suppl. 45, 225s
Year: 2003

Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis
Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis
Year: 2010

Lung fibroblasts regulate the urokinase-type plasminogen activator receptor (uPAR) expression of alveolar epithelial cells and endothelial cells
Source: Eur Respir J 2006; 28: Suppl. 50, 397s
Year: 2006

The relation between plasminogen activator inhibitor-1 (PAI-1) and inflammatory markers in COPD: A possible risk factor of inflammation-induced thrombosis
Source: International Congress 2017 – Systemic and airway biomarkers
Year: 2017

The mechanism of plasminogen activator inhibitor type-1 (PAI-1) Cys mutants inhibitory activity towards lung capillaries endothelial cells (HMVEC-L)
Source: Eur Respir J 2005; 26: Suppl. 49, 93s
Year: 2005

Enoxaparin reduced ventilation-induced plasminogen activator inhibitor-1
Source: Annual Congress 2009 - Crossing the line: alveolo-capillary barrier control in acute lung injury
Year: 2009



SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor growth and lung metastasis formation probably through the reduction of tumor angiogenesis
Source: Annual Congress 2011 - Progress in pathology of lung cancer
Year: 2011

Proapoptotic and anti-proliferative effect of the stable plasminogen activator inhibitor type 1 (PAI-1) mutant on the lung cancer and endothelial cells
Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease?
Year: 2009


Plasminogen activator inhibitor type 1 (PAI-1) is a negative regulator of lung cancer cells growth due to its anti-proteinase activity
Source: Annual Congress 2008 - Novel targets in the molecular pathology of lung cancer and COPD
Year: 2008


Plasminogen activator inhibitor (PAI)-1 is expressed in human eosinopils stimulated by TGF-β
Source: Eur Respir J 2006; 28: Suppl. 50, 590s
Year: 2006

Influence of prostaglandin E2 on cell surface urokinase-type plasminogen activator expression and activity in lung adenocarcinoma cell line
Source: Eur Respir J 2005; 26: Suppl. 49, 457s
Year: 2005

Regulation of plasminogen activator activity by inflammatory mediators in lung epithelial cells
Source: Eur Respir J 2005; 26: Suppl. 49, 343s
Year: 2005

Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 suppresses allergic asthma in a murine model
Source: Annual Congress 2010 - Animal models of asthma and lung inflammation
Year: 2010

Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma
Source: Eur Respir J 2016; 47:1568-1571
Year: 2016


Soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in exacerbated COPD
Source: International Congress 2018 – New predictors of morbidity and mortality in COPD
Year: 2018



Urokinase type plasminogen activator improves airway inflammation and mucin expression in a murine asthma model
Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung
Year: 2010